Biocon Insulin Aspart US Opportunity: 'Not Completely Lost But Not The Best Situation'
Biocon may not be able to make it to the current contracting cycle in the US for its Viatris-partnered biosimilar aspart, but all is not lost, the management indicates. The Indian firm is also buoyant about the prospects of taking its franchise of potentially interchangeable recombinant human insulin to the US.
You may also be interested in...
Viatris remains committed to completing the sale of its global biosimilars unit to Biocon Biologics, while continuing efforts to generate up to $9bn in pre-tax proceeds by the end of 2023 from divestments.
A busy August brings patent expiries, biosimilar target action dates and the potential for a major change to biosimilar prescribing guidelines in Germany.
Private sector efforts to lower cost sharing for insulin continue but patient advocates and lawmakers still believe legislation is needed to tackle the issue in a comprehensive way.